following an abbreviated submission:
plerixafor (Mozobil®) is accepted for use within NHSScotland.
Indication under review: in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children aged 1 year to <18 years with lymphoma or solid malignant tumours, either:
- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilisation with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or
- who previously failed to collect sufficient haematopoietic stem cells.
SMC has previously accepted plerixafor for use in adults, in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly (SMC No. 594/09).
Download detailed advice634KB (PDF)
Medicine details
- Medicine name:
- plerixafor (Mozobil)
- SMC ID:
- SMC2249
- Indication:
In combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children aged 1 year to <18 years with lymphoma or solid malignant tumours, either:
- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilisation with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or
- who previously failed to collect sufficient haematopoietic stem cells.- Pharmaceutical company
- Sanofi-Aventis
- BNF chapter
- Nutrition and blood
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 February 2020